Nexus Medical Partners

Zipit Wireless, Inc. is a technology company based in Greenville, South Carolina, specializing in critical messaging and Internet of Things (IoT) solutions. Founded in 2007, the company provides instant communication systems designed for critical situations, catering to various sectors, including healthcare, education, government, and hospitality. Its Enterprise Critical Messaging Solution enables two-way communication for organizations such as hospitals and emergency services. In addition to messaging services, Zipit Wireless offers cloud-based software and cellular services that support IoT products, including a subscription billing and activations platform for managing cellular activations and subscriptions. The company also develops network-connected devices, such as wireless trail cameras and medication adherence devices, which can be managed remotely through web portals or mobile applications. With a focus on enabling businesses to optimize their mobile operations, Zipit Wireless markets its technology solutions globally.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

Sabal Medical is a healthcare platform focused on enhancing the safety and efficiency of medication administration within hospitals and long-term care facilities. The company provides advanced pharmacy and nursing technology that facilitates improved communication between nurses and pharmacists. Its mobile medication tracking services utilize barcode verification to ensure that patients receive the correct medications and dosages at the appropriate times, thereby reducing the risk of medication errors. By streamlining the medication administration process, Sabal Medical aims to support healthcare organizations in delivering safer and more effective patient care.

Zipit Wireless, Inc. is a technology company based in Greenville, South Carolina, specializing in critical messaging and Internet of Things (IoT) solutions. Founded in 2007, the company provides instant communication systems designed for critical situations, catering to various sectors, including healthcare, education, government, and hospitality. Its Enterprise Critical Messaging Solution enables two-way communication for organizations such as hospitals and emergency services. In addition to messaging services, Zipit Wireless offers cloud-based software and cellular services that support IoT products, including a subscription billing and activations platform for managing cellular activations and subscriptions. The company also develops network-connected devices, such as wireless trail cameras and medication adherence devices, which can be managed remotely through web portals or mobile applications. With a focus on enabling businesses to optimize their mobile operations, Zipit Wireless markets its technology solutions globally.

Zipit Wireless, Inc. is a technology company based in Greenville, South Carolina, specializing in critical messaging and Internet of Things (IoT) solutions. Founded in 2007, the company provides instant communication systems designed for critical situations, catering to various sectors, including healthcare, education, government, and hospitality. Its Enterprise Critical Messaging Solution enables two-way communication for organizations such as hospitals and emergency services. In addition to messaging services, Zipit Wireless offers cloud-based software and cellular services that support IoT products, including a subscription billing and activations platform for managing cellular activations and subscriptions. The company also develops network-connected devices, such as wireless trail cameras and medication adherence devices, which can be managed remotely through web portals or mobile applications. With a focus on enabling businesses to optimize their mobile operations, Zipit Wireless markets its technology solutions globally.

Sabal Medical is a healthcare platform focused on enhancing the safety and efficiency of medication administration within hospitals and long-term care facilities. The company provides advanced pharmacy and nursing technology that facilitates improved communication between nurses and pharmacists. Its mobile medication tracking services utilize barcode verification to ensure that patients receive the correct medications and dosages at the appropriate times, thereby reducing the risk of medication errors. By streamlining the medication administration process, Sabal Medical aims to support healthcare organizations in delivering safer and more effective patient care.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

Selah Technologies, LLC is an advanced materials manufacturing company developing and commercializing two proprietary nanotechnologies. Selah Dotsâ„¢ are patent-pending photoluminescent carbon-based nanoparticles. Selah Tubesâ„¢ are enriched single-walled nanotubes with precisely engineered electronic properties protected under US Patent No. 7,374,685. Our mission is to consistently deliver high quality nanomaterials and nano-enabled products to the global marketplace. Our growth strategy is to leverage relationships with market leading companies to establish mutually beneficial joint research and development agreements. Our strategy is founded in the conviction that early successes in our target markets will occur via exploitation of nanomaterials in established applications in which their incorporation is both useful and compelling, and addresses needs that nanotechnology can fulfill either immediately or in the very short term.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Francisco, California, focused on the discovery and development of small-molecule antiviral therapeutics for viral infections, particularly hepatitis C virus (HCV) and HIV. Founded in 2006, the company is dedicated to creating innovative therapies, including pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride, which target specific proteins of the HCV. Presidio's antiviral therapeutics are designed for daily oral dosing and can be used in combination with other antiviral treatments to enhance efficacy and combat viral resistance. Through its efforts, Presidio aims to provide effective drug therapies to patients dealing with various strains of hepatitis.

Cequent Pharmaceuticals is an early-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA interference (RNAi) therapies to prevent and treat various human diseases, including inflammatory conditions and cancer. Founded in 2006, Cequent is pioneering innovative therapeutics utilizing its proprietary TransKingdom RNA interference (tkRNAi) technology, which safely and effectively deactivates specific disease-causing genes. This technology employs non-pathogenic bacteria to produce and deliver RNAi directly into cells. Currently, Cequent's leading drug candidates are in pre-clinical development, specifically targeting colon cancer prevention and inflammatory bowel disease. The company's scientific foundation is rooted in significant research conducted at the Institut Pasteur in Paris and the Beth Israel Deaconess Medical Center/Harvard Medical School.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.

Magellan Diagnostics is a medical device company specializing in the development and manufacture of point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. Based in North Billerica, Massachusetts, the company offers products such as LeadCare II for blood lead testing, LeadCare Ultra for laboratory use, and LeadCare Plus for smaller volume laboratories. Magellan Diagnostics also provides various analytical services, including monitoring exposure to lead and heavy metals. The company's mission is to identify and protect individuals at risk of lead poisoning, a preventable health threat. Founded in 2004 as Magellan Biosciences, Inc., the company has roots tracing back to the late 1960s when it was originally established as ESA, Inc. by MIT graduates.

Neurotech is a privately held biotechnology company focused on developing innovative therapeutics for chronic retinal diseases, which are characterized by significant unmet medical needs. The company has created a novel therapy system that features an ocular implant designed to continuously produce therapeutic proteins within the eye. This technology allows therapeutic cells to endure challenging conditions associated with these diseases, effectively replacing or supporting the function of damaged target cells or tissue. By doing so, Neurotech aims to enhance the quality of life for individuals suffering from chronic retinal disorders, addressing a substantial market opportunity within the field of ophthalmology.

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.